Pharmacogenetics articles within Nature Reviews Cardiology

Featured

  • Review Article |

    Drug response and the development of adverse effects can vary between individuals. The use of pharmacogenomics should aid in the delivery of the right drug to the right patient, but clinical implementation of pharmacogenetic principles has been difficult, owing to a lack of randomized clinical trials that demonstrate benefit of this approach. This article reviews the use of pharmacogenetic markers in randomized clinical trials, highlighting studies related to cardiovascular disease.

    • Naveen L. Pereira
    • , Daniel J. Sargent
    •  & Charanjit S. Rihal

  • News & Views |

    Two types of genetic risk scores (GRS) have been devised to identify patients who will benefit most from cardiovascular-drug treatment: one related to the intermediate phenotype within a causal pathway, and another related to the expected clinical event. These GRS are promising and might have clinical implications for future practice.

    • J. Wouter Jukema
    •  & Stella Trompet

  • Consensus Statement |

    East Asian patients are known to have differing risks of thrombophilia and bleeding compared with white patients, but few have been included in phase III trials of P2Y12inhibitors. Therefore, the World Heart Federation has produced this evidence-based review and expert consensus statement to determine the antiplatelet treatment strategies that are most appropriate for East Asian patients with acute coronary syndrome or undergoing percutaneous coronary intervention.

    • Glenn N. Levine
    • , Young-Hoon Jeong
    •  & Sidney C. Smith Jr

  • News & Views |

    Much debate surrounds the utility of CYP2C19*2 genotyping in patients receiving clopidogrel after coronary artery stenting. The effectiveness of its use in a point-of-care setting has now been examined and, given the substantial incremental suppression of platelet reactivity achieved, its routine use might soon be a reality.

    • Paddy M. Barrett
    •  & Eric J. Topol

  • News & Views |

    Commenting on the results of their meta-analysis, Holmes et al. suggest that CYP2C19 genotype does not affect clinical outcome in patients receiving clopidogrel therapy. However, we do not believe that the data support this conclusion; an association between genotype and outcome remains plausible and could be considered when choosing treatment.

    • Jurriën M. ten Berg
    •  & Vera H. Deneer

  • Review Article |

    Evidence is increasing that genetic variation between patients underlies the considerable variability in their response to antiplatelet agents, and, therefore, in clinical outcomes. Drs Ahmad, Voora, and Becker review the genetic loci that seem to have a role in determining platelet response; genes that are involved in the absorption, metabolic activation, and biological activity of aspirin and clopidogrel. Finally, they discuss, in the context of ongoing clinical trials, the merits and potential dangers of using commercial genetic testing and pharmacogenetics to personalize antiplatelet therapy to individual patients.

    • Tariq Ahmad
    • , Deepak Voora
    •  & Richard C. Becker

Browse broader subjects

Browse Pharmacogenetics across other nature.com journals